A Crosstalk Correcting Router That Uses Online Noise Simulation to Route High Speed Multichip Modules

Existing MultiChip Module (MCM) auto-routers either ignore crosstalk or use over simplified crosstalk approximations. Of the routers that do consider crosstalk, very few have the capability to correct crosstalk problems after they occur. This dissertation describes a router that not only has an internal crosstalk model for high speed MCMs which is more accurate than that of other existing routers, but also has the capability to use an online simulator to more accurately determine noise levels. After crosstalk problems occur, the router has the ability to correct these problems. Through memory usage reductions and routing efficiency improvements, this maze router has proven to be a good alternative to the current method of manual routing for very large, high-speed MCM designs

A Crosstalk Correcting Router that Uses Online Noise Simulation to Route High-Speed Multichip Modules

Existing Multi Chip Module (MCM) auto-routers either ignore crosstalk or use over-simplified crosstalk approximations. Of the routers that do consider crosstalk, very few have the capability to correct crosstalk problems after they occur. This dissertation describes a router that not only has an internal crosstalk model for high speed MCMs which is more accurate than that of other existing routers, but also has the capability to use an online simulator to more accurately determine noise levels. After crosstalk problems occur, the router has the ability to correct these problems. Through memory usage reductions and routing efficiency improvements, this maze router has proven to be a good alternative to the current method of manual routing for very large, high-speed MCM designs

Digital Signal Processing

Contains reports on twelve research projects.U. S. Navy - Office of Naval Research (Contract N00014-75-C-0951)National Science Foundation (Grant ENG76-24117)National Aeronautics and Space Administration (Grant NSG-5157)Joint Services Electronics Program (Contract DAABO7-76-C-1400)U.S. Navy-Office of Naval Research (Contract N00014-77-C-0196)Woods Hole Oceanographic InstitutionU. S. Navy - Office of Naval Research (Contract N00014-75-C-0852)Department of Ocean Engineering, M.I.T.National Science Foundation subcontract to Grant GX 41962 to Woods Hole Oceanographic Institutio

The effect on survival of continuing chemotherapy to near death

<p>Abstract</p> <p>Background</p> <p>Overuse of anti-cancer therapy is an important quality-of-care issue. An aggressive approach to treatment can have negative effects on quality of life and cost, but its effect on survival is not well-defined.</p> <p>Methods</p> <p>Using the Surveillance, Epidemiology, and End Results-Medicare database, we identified 7,879 Medicare-enrolled patients aged 65 or older who died after having survived at least 3 months after diagnosis of advanced non-small cell lung cancer (NSCLC) between 1991 and 1999. We used Cox proportional hazards regression analysis, propensity scores, and instrumental variable analysis (IVA) to compare survival among patients who never received chemotherapy (n = 4,345), those who received standard chemotherapy but not within two weeks prior to death (n = 3,235), and those who were still receiving chemotherapy within 14 days of death (n = 299). Geographic variation in the application of chemotherapy was used as the instrument for IVA.</p> <p>Results</p> <p>Receipt of chemotherapy was associated with a 2-month improvement in overall survival. However, based on three different statistical approaches, no additional survival benefit was evident from continuing chemotherapy within 14 days of death. Moreover, patients receiving chemotherapy near the end of life were much less likely to enter hospice (81% versus 51% with no chemotherapy and 52% with standard chemotherapy, P < 0.001), or were more likely to be admitted within only 3 days of death.</p> <p>Conclusions</p> <p>Continuing chemotherapy for advanced NSCLC until very near death is associated with a decreased likelihood of receiving hospice care but not prolonged survival. Oncologists should strive to discontinue chemotherapy as death approaches and encourage patients to enroll in hospice for better end-of-life palliative care.</p